NCT01990534View on ClinicalTrials.gov

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 14, 2014

Primary Completion Date

March 24, 2016

Study Completion Date

March 12, 2020

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Brentuximab vedotin IV infusion

Trial Locations (18)

Unknown

Prague

Brno

Heidelberg

Cologne

George Town

Ampang

Kuala Lumpur

Gdansk

Krakow

Warsaw

Pamplona

Madrid

Bangkoknoi

Patumwan

Ratchathewi

Izmir

Ankara

Izmir

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01990534 - A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter